In October 2020, CStone signed a licensing agreement with LigaChem for the development and commercialization of CS5001 which was originally generated by collaboration of LigaChem and ABL Bio, both South Korea-based biotech companies. Under the agreement, CStone obtains the exclusive global right to develop and commercialize CS5001 outside the Republic of Korea.